ORIGIN-3 has arrived to NephJC with atacicept in IgAN.
A strong step toward upstream, BAFF/APRIL-targeted therapy that tackles IgAN pathophysiology right at the source. Early signals look promising!
Check out the visual abstract by Clemens Weber
ORIGIN-3: The Visual Abstract